Immatics to Present Key Updates at Upcoming Melanoma Event
![Immatics to Present Key Updates at Upcoming Melanoma Event](https://investorshangout.com/images/blog/ihnews-Immatics%20to%20Present%20Key%20Updates%20at%20Upcoming%20Melanoma%20Event.jpg)
Immatics Set for Major Presentation at Melanoma Congress
Immatics N.V. (NASDAQ: IMTX), a leading biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced an exciting upcoming oral presentation at the International Congress of the Society for Melanoma Research. This presentation will specifically highlight the updated clinical data for their promising cell therapy candidate, ACTengine® IMA203, which targets the preferentially expressed antigen in melanoma (PRAME).
Presentation Details
The oral presentation is scheduled for October 11, 2024, during the Plenary Session 1, which focuses on Developmental Immunotherapy including various innovative approaches. The time slot allotted is from 8:00 to 8:20 AM Central Daylight Time. Dr. Martin Wermke from the University Hospital Dresden, Germany, will lead the presentation, detailing the significant advancements in the treatment of PD1-refractory metastatic melanoma.
Understanding ACTengine IMA203
ACTengine® IMA203 is an autologous T cell product featuring a genetically modified T cell receptor designed to identify a specific HLA-A*02-presented peptide derived from PRAME. This peptide is notably prevalent in numerous solid tumors and is expressed at high levels within tumor cells. Immatics utilized its innovative XPRESIDENT® platform for mass spectrometry-based target discovery, enhancing the identification of this crucial target.
Currently, ACTengine® IMA203 is undergoing evaluation in a Phase 1 clinical trial, where it is being tested both as a monotherapy and in a second-generation variant (IMA203CD8). This innovative approach involves co-transducing IMA203-engineered T cells with a CD8?? co-receptor, allowing the therapy to tap into the strengths of both CD4+ and CD8+ T cell populations to combat cancer more effectively. Notably, Immatics has chosen to deprioritize the combination of IMA203 with immune checkpoint inhibitors, focusing on its standalone efficacy.
Company Vision and Commitment
Immatics is driven by its commitment to developing targeted cancer immunotherapies through meticulous target discovery and the engineering of potent T cell receptors. Their objective is to foster robust T cell responses against identified cancer targets, and this dedication lies behind the development of their promising pipeline of Adoptive Cell Therapies and TCR Bispecifics. Through strategic partnerships with leading pharmaceutical companies, Immatics aims to bring transformative therapies to patients facing cancer diagnoses.
Stay Updated with Immatics
Immatics plans to leverage its official website as a key channel for sharing non-public material information. Interested parties can also stay informed about company developments by following them on various social media platforms, including X, Instagram, and LinkedIn.
Contact Information
For media inquiries: Trophic Communications, Phone: +49 171 3512733, Email: immatics@trophic.eu
For investor relations: Jordan Silverstein, Head of Strategy, Immatics N.V., Phone: +1 346 319-3325, Email: InvestorRelations@immatics.com
Frequently Asked Questions
What is the focus of the presentation at the Congress?
The presentation will discuss updated clinical data for ACTengine® IMA203, targeting PRAME in metastatic melanoma.
Who will be presenting the data?
Dr. Martin Wermke from the University Hospital Dresden will present the findings at the congress.
When will the presentation take place?
The oral presentation is set for October 11, 2024, from 8:00 to 8:20 AM CDT.
What is the significance of ACTengine® IMA203?
ACTengine IMA203 represents a significant advancement in tailored cancer treatments, focusing on PRAME, which is expressed in many tumors.
How can I stay updated on Immatics' developments?
Follow Immatics on their social media platforms or visit their website for the latest news and updates.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Efficient Junk Removal Services Launch in Austin by Black Cat
- Booking Holdings Inc. Experiences Significant Stock Boost
- Transforming Spaces: Cleanzen Boston’s New Identity
- Samsara Inc. Surprises Investors with Strong Q2 Earnings Boost
- Spartan Capital Securities Achieves Major Milestones in August
- Pinnacle Treatment Centers Welcomes New Leadership Team
- Strategic Partnership Enhances P&C Management for Agencies
- Insurtech Market Growth: Future Innovations and Trends Ahead
- Growth of Electronic Materials and Chemicals Market Insights
- Montreal's Real Estate Market Thrives Amid Low Interest Rates
Recent Articles
- Canada Nickel Secures EDC Interest for $500 Million Financing
- Axogen Submits Pioneering Biologics License Application for Avance
- ABM Industries Posts Q3 Results: Revenue Growth and EPS Increase
- Avidian Gold's Strategic Share Consolidation Announcement
- Krystal Biotech to Showcase Innovations at Upcoming Conference
- Aya Gold & Silver Reveals Progress on Zgounder Mine Expansion
- Entrada Therapeutics Empowers Duchenne Community with Grants
- Ji Xing Pharmaceuticals Reports Breakthrough Phase 3 Findings
- Beasley Broadcast Group Announces New Offers and Exchange Plans
- Edible Garden to Exhibit Kick Sports Nutrition Line at ECRM
- Tonix Pharmaceuticals Introduces New Campaign for Migraine Relief
- Innovative Advances in Cancer Treatment by Nurix Therapeutics
- Nasdaq Introduces New Revenue Recognition for AxiomSL
- Wabash Plans Legal Response After Court Verdict on Accident
- Foresight Technology VCT PLC Launches Subscription Prospectus
- Explore Exciting Tech Innovations You May Have Missed
- Canada Nickel Company Secures Significant Financial Interest
- Future Forecast: Energy Management Systems Surge to $84 Billion
- Market Uncertainty Ahead of Job Reports Pressures Futures
- Comparing Today's High-Quality Stocks to 2008's Landscape
- Market Reactions Ahead of Employment Data and Economic Trends
- Exploring High-Yield Dividend Stocks for Steady Income
- Exploring the Future of RFID Technology in Pharmaceuticals
- Hut 8 Updates Mining Capacity and Future Growth Plans
- Carbon Revolution Enhances Growth with $5 Million Investment
- Hut 8 Operations Report Reveals Strong Performance Metrics
- BitFuFu's Active Participation in September Investor Conferences
- Fanhua BluePlus and Biotecan: A Collaboration for Health Innovation
- AJ Thomas Named President of Healthcare Development at BR
- Trintech: Leading the Way in Financial Close Innovation
- Forecasting the Growth of the Packaging Films Industry
- Leading the Charge in Financial Close Management Innovations
- Discover Exciting Retail News: Highlights You Can't Miss
- Hisense Laser TV Redefines Home Entertainment with Innovative Tech
- Zenas BioPharma Aims for Major IPO with 11.76M Shares
- Volkswagen's Bold Moves Challenge Germany's Industrial Stability
- Sectra AB Sees Significant Earnings Boost in First Quarter
- Stock Market Pulse: India Sees Decline with Nifty 50 Drop
- Exploring the Hidden Costs of Technology's Economic Benefits
- Navigating the AI Market: Insights and Challenges Ahead
- Why Investing in Pfizer Today Could Be a Smart Move
- Market Reaction: Anticipation Builds for Jobs Data Release
- Semiconductor Stocks Take a Hit: Insights and Implications
- Salesforce Strategically Acquires Own Company to Boost Security
- BRP Reports Second Quarter Results for Fiscal Year 2025
- Exploring the Future of Single-Cell Analysis Industry Growth
- Cheetah Mobile's Upcoming Financial Report and Earnings Call
- Essential Financial Updates and Insights You Should Know
- LONGi's Innovative Solar Technology Receives Multiple Accolades
- CHINT Drives Sustainable Energy Innovation at Cigré 2024